SOURCE: Accelovance

Accelovance

October 12, 2016 04:00 ET

Accelovance Investment Further Enhances Efficient and Step-Wise Approach to Early Phase Oncology Services

ROCKVILLE, MD--(Marketwired - October 12, 2016) - Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in oncology, vaccines, and general medicine; announced today it has completed full integration of THERAMetrics, acquired on May 25, 2016, further enhancing its early phase oncology services.

The integration of THERAMetrics' European staff enables Accelovance to meet emerging trends and client needs in operationalizing combined Phase I/II protocols involving a "step‐wise approach" with joint US and EU involvement. These integrated services support our existing strategic approaches to better serve early phase oncology clients through our scientific and regulatory expertise, our strategic site and network relationships, and the therapeutic expertise of our team members. Accelovance is focused on serving Sponsors with oncology assets, helping drive their IND - Phase II candidates to an early value inflection point. This stage of development is currently underserved by most CROs.

Accelovance continues to forge new network and site alliances (including just-in-time site activation and enrollment), optimize its clinical technology suite to provide enhanced transparency and decision making, and apply financially and operationally efficient processes to accelerate oncology drug development, thereby providing more value to our Sponsors. For a more detailed list of Accelovance's early phase oncology services, please visit Accelovance's website.

Steve Trevisan, Accelovance CEO, stated, "Early Phase Oncology support and focus remains underserved by most CROs, and Sponsors are actively looking for CRO partners like Accelovance that offer tangible differentiators and, most importantly, are able to exceptionally execute these trials in the most expeditious, cost sensitive way while ensuring patient safety. We will continue to invest in oncology-dedicated staff, expand our strategic site and network relationships, and continuously assess our technology and processes to ensure we effectively execute and provide value to our Sponsors."

About Accelovance

Accelovance, Inc., headquartered in Rockville, MD, is an industry award-winning global Contract Research Organization (CRO) focused primarily in oncology, vaccine, and general medicine clinical research. As a clinical services provider to the pharmaceutical and biotechnology industries, Accelovance offers comprehensive clinical development services including management and implementation of Phase I-IV clinical trials, supportive research centers, and a clinical engagement solution utilized for recruitment, post-marketing surveillance, and long-term survival follow-up. For more information, visit the company's Web site at www.accelovance.com.

Contact Information

  • Press Contact:
    Michael Keens
    EVP Global Business Development
    +1.240.238.4941
    mkeens@accelovance.com
    Twitter: @Accelovance